Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Summary

Primary Objective: Injection Site Tolerability Secondary Objective: * To assess the safety profile of alirocumab SAR236553 (REGN727) * To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)

Timeline

Start

2011-06

Primary completion

2011-09

Completion

2011-09

Drugs

Indications